Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 331 to 345 of 721 results for must

  1. Faecal microbiota transplant for recurrent Clostridioides difficile infection (HTG638)

    Evidence-based recommendations on faecal microbiota transplant for recurrent Clostridioides difficile infection.

  2. Aquilion PRIME CT scanner for imaging coronary artery disease in adults in whom imaging is difficult (MIB53)

    NICE has developed a medtech innovation briefing (MIB) on the Aquilion PRIME CT scanner for imaging coronary artery disease in adults in whom imaging is difficult .

  3. Somatom Definition Edge CT scanner for imaging coronary artery disease in adults in whom imaging is difficult (MIB54)

    NICE has developed a medtech innovation briefing (MIB) on the Somatom Definition Edge CT scanner for imaging coronary artery disease in adults in whom imaging is difficult .

  4. ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot (MIB56)

    NICE has developed a medtech innovation briefing (MIB) on the ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot

  5. Guidance on the use of electroconvulsive therapy (TA59)

    Evidence-based recommendations on electroconvulsive therapy (ECT) for treating catatonia, prolonged or severe manic episodes or schizophrenia in adults.

  6. Babies, children and young people's experience of healthcare (NG204)

    This guideline describes good patient experience for babies, children and young people, and makes recommendations on how it can be delivered. It aims to make sure that all babies, children and young people using NHS services have the best possible experience of care. It is recognised that parents and carers play a key role, and where appropriate, we took their views into account when developing the recommendations.

  7. Holistic assessment in the community:- What is the clinical and cost effectiveness of a community holistic assessment and intervention for people living with high levels of multimorbidity?

    frailty, people with high levels of multimorbidity or polypharmacy).Such trials must be rigorous, with clear identification and...

  8. Fungitell for antifungal treatment stratification (MIB118)

    NICE has developed a medtech innovation briefing (MIB) on Fungitell for antifungal treatment stratification .

  9. Baricitinib for treating moderate to severe atopic dermatitis (TA681)

    Evidence-based recommendations on baricitinib for treating moderate to severe atopic dermatitis in adults.

  10. Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1015)

    Evidence-based recommendations on teclistamab (Tecvayli) for relapsed and refractory multiple myeloma after 3 or more treatments in adults.

  11. Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)

    Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and high-dose imatinib (Glivec) for treating imatinib-resistant or intolerant chronic myeloid leukaemia in adults.

  12. Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable (TA1097)

    Evidence-based recommendations on enfortumab vedotin (Padcev) with pembrolizumab (Keytruda) for untreated unresectable or metastatic urothelial cancer in adults when platinum-based chemotherapy is suitable.

  13. Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors (TA1146)

    Evidence-based recommendations on ripretinib (Qinlock) for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors in adults.

  14. Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma (TA1113)

    Evidence-based recommendations on glofitamab (Columvi) plus gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma not otherwise specified in adults.

  15. Tobacco: preventing uptake, promoting quitting and treating dependence (NG209)

    This guideline covers support to stop smoking for everyone aged 12 and over, and help to reduce people's harm from smoking if they are not ready to stop in one go. It also covers ways to prevent children, young people and young adults aged 24 and under from taking up smoking.